Morrison Cancer Center, Mary Lanning Healthcare, Hastings, NE.
Section of Thoracic Surgery, University of Nebraska Medical Center, Omaha, NE.
Oncology (Williston Park). 2020 Sep 15;34(9):347-351. doi: 10.46883/ONC.2020.3409.0347.
Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.
乳腺转移来自于非乳腺恶性肿瘤较为罕见,在已发表的文献中报道的发病率为 0.4%至 1.3%。最常转移至乳腺的原发性恶性肿瘤为白血病、淋巴瘤和恶性黑色素瘤。在此,我们报告一例通过筛查性乳房 X 线摄影术发现的非常罕见的转移性表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)病例。该患者最初被诊断为临床 IIIA 期 NSCLC,并接受了新辅助放化疗,随后进行了根治性手术。本病例有几个有趣的方面,并讨论了 EGFR 突变型 NSCLC 中不断发展的辅助和一线转移性治疗选择。